A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 714 participants.

Also called NCT05182840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 714 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05182840
  • EudraCT 2021-001434-19
Other papers using this trial's data
  • Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses Diabetes, obesity & metabolism, 2026-07 DOI, PubMed 42086479, PMC13243991 In the PMC Open Access subset under CC BY-NC.
  • Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial Lancet (London, England), 2024-01-27 DOI, PubMed 38109916
  • Pharmacodynamics of vicadrostat for aldosterone synthase inhibition in patients with CKD European journal of endocrinology, 2026-01-06 DOI, PubMed 41436034

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Finland, Germany, Greece, Hong Kong SAR China, Hungary, India, Italy, Japan, Malaysia, Mexico, Norway, Philippines, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Switzerland, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05182840. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-11 (actual); primary completion 2023-06-19 (actual). Results posted on 2024-08-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
Condition
Kidney Disease, Chronic
Intervention (Drug)
BI 690517
Intervention (Drug)
Placebo to BI 690517
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo to empagliflozin
Lead sponsor
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct05182840
Content hash
aaa8db4c28840f8eb3339fefea890d7a948b2c646b4c859e4b348b5f013fc5d1